<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375580</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1201-8245</org_study_id>
    <nct_id>NCT03375580</nct_id>
  </id_info>
  <brief_title>Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD</brief_title>
  <official_title>Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in Nonalcoholic Fatty Liver disease-a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangdong Pharmaceutical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu
      Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement
      in NAFLD parameters and changes in intestinal functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu
      Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement
      in NAFLD parameters and changes in intestinal functions. In this study, the investigators
      will (1)evaluate the relationship between the function of intestinal mucosal barrier, SIBO,
      and NAFLD;(2)assess the effects of Compound Zhenzhu Tiaozhi capsules on intrahepatic fat
      content, hepatic noninvasive score, liver biochemical parameters, blood lipid, and insulin
      resistance. To evaluate the therapeutic effects of Compound Zhenzhu Tiaozhi capsules on the
      treatment of NAFLD, and determine whether the risk stratification of atherosclerotic
      cardiovascular disease (ASCVD) and quality of life (using the 36-Item Short Form Health
      Survey [SF-36]) can be improved in NAFLD patients with Compound Zhenzhu Tiaozhi capsules;(3)
      compare the therapeutic effects of Compound Zhenzhu Tiaozhi capsules with conventional
      medications in the treatment of NAFLD, and to compare their efficacies in improving the risk
      stratification of ASCVD and quality of life, as assessed by the SF-36; (4) analyze the
      relationship of Compound Zhenzhu Tiaozhi capsules in improving NAFLD and parameters related
      to the function of the intestinal mucosal barrier and SIBO.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat attenuation index</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>The fat attenuation index will be used to assess the therapeutic efficacy. A normal fat attenuation index is defined as &lt; 240 db/m, mild is 240-264 db/m, moderate is 265-294 db/m, and severity is &gt; 295 db/m.We will detect the fat attenuation index at 6 months following treatment. Effective: fat attenuation index is reduced by a level or more (example: moderate to mild). Invalid: fails to meet the effective standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>detecting the serum level of triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cholesterol</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>detecting the serum level of cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipoproteins</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>including chylomicron (CM), very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrogen/methane breath testing</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>breath testing for SIBO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at 6 months following therapy</time_frame>
    <description>The quality of life of the patients before and after treatment will be assessed using the 36-Item Short Form Health Survey and compared to assess the improvement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>TLC group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>transform life custom (TLC) group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC + metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transform life custom (TLC) combined with 0.5g metformin, PO tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC + CZT capsules group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC + simvastatin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transform life custom (TLC) combined with 20mg simvastatin, PO qn</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TLC</intervention_name>
    <description>transform life custom (TLC)</description>
    <arm_group_label>TLC group</arm_group_label>
    <arm_group_label>TLC + metformin group</arm_group_label>
    <arm_group_label>TLC + CZT capsules group</arm_group_label>
    <arm_group_label>TLC + simvastatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>0.5g metformin group，PO tid</description>
    <arm_group_label>TLC + metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Zhenzhu Tiaozhi capsule</intervention_name>
    <description>Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.</description>
    <arm_group_label>TLC + CZT capsules group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>20mg simvastatin, PO qn</description>
    <arm_group_label>TLC + simvastatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        clinical diagnosis of simple steatosis or NASH 18 to 75 years old serum alanine
        transaminase (ALT)≤2 times the upper limit of normal

        Exclusion Criteria:

        other chronic liver diseases serious complications in other organs malignant tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xingxiang He, Dr.</last_name>
    <email>hexingxiangtongxun@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guobiao Huang</last_name>
      <phone>86-20-39352064</phone>
      <email>153706227@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangdong Pharmaceutical University</investigator_affiliation>
    <investigator_full_name>He Xingxiang</investigator_full_name>
    <investigator_title>Director of the Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

